Adaptive Biotechnologies Corporation ADPT

Company Overview

Adaptive Biotechnologies Corporation is a publicly traded biotechnology company that focuses on decoding the adaptive immune system to enable precise diagnostics and therapeutic discovery. The company operates at the intersection of biotechnology, genomics, and immunology, leveraging proprietary immune sequencing and data analytics to profile T-cell and B-cell receptors at scale. Its core value proposition is the ability to translate immune repertoire data into clinically actionable insights.

The company’s primary revenue drivers are immune-based diagnostic tests and research services sold to biopharmaceutical companies, academic institutions, and clinical laboratories. Adaptive Biotechnologies was founded in 2009 and built its early capabilities around high-throughput immune sequencing. Over time, it expanded from research applications into regulated clinical diagnostics, particularly in oncology and immunology, evolving into a platform company with both diagnostics and biopharma partnerships.